Our Science – Kohn Website
Elise C. Kohn, M.D.
Selected Publications |
 |
| 1)
Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC. Feasibility and safety of sequential research-related tumor core biopsies in clinical trials. Cancer. 119: 1357-64, 2013. [Journal] |
|
| 2)
Kohn EC, Hurteau J. Ovarian cancer : making its own rules-again. Cancer. 119: 474-6, 2013. [Journal] |
|
| 3)
Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Mol. Cell Proteomics. [Epub ahead of print], 2013. [Journal] |
|
| 4)
Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC. Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer. 118: 1543-53, 2012. [Journal] |
|
| 5)
Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, Alessandro R, Kohn EC. Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis. 15: 33-45, 2012. [Journal] |
|
| 6)
Yu M, Henning R, Walker A, Kim G, Perroy A, Alessandro R, Virador V, Kohn EC. L-Asparaginase Inhibits Invasive And Angiogenic Activity And Induces Autophagy In Ovarian Cancer. J Cell Mol Med. 16: 2369-78, 2012. [Journal] |
|
| 7)
Annunziata CM, Kohn EC, Lorusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs. [Epub ahead of print], 2012. [Journal] |
|
| 8)
Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin. Cancer Res. 18: 2099-107, 2012. [Journal] |
|
| 9)
Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study. Gynecol. Oncol. 122: 89-94, 2011. [Journal] |
|
| 10)
Corrado C, Raimondo S, Flugy AM, Fontana S, Santoro A, Stassi G, Marfia A, Iovino F, Arlinghaus R, Kohn EC, Leo GD, Alessandro R. Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism. Cancer Lett. 300: 205-14, 2011. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/12/2013.
